Robert M. Davis - 04 Feb 2026 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role: Chairman, CEO & President, Director
Signature: /s/ Kelly E. W. Grez as Attorney-in-Fact for Robert M. Davis
Issuer symbol: MRK
Transactions as of: 04 Feb 2026
Net transactions value: -$5,599,327
Form type: 4
Filing time: 06 Feb 2026, 16:05:31 UTC
Previous filing: 28 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Davis Robert M	Chairman, CEO & President, Director	MERCK & CO., INC., 126 EAST LINCOLN AVENUE, RAHWAY	/s/ Kelly E. W. Grez as Attorney-in-Fact for Robert M. Davis	06 Feb 2026	0001363076

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRK	Common Stock	Sale	$1,757,407	-14,972	-3%	$117.38	476,064	04 Feb 2026	Direct	F1
transaction	MRK	Common Stock	Sale	$3,841,920	-32,462	-6.8%	$118.35	443,602	04 Feb 2026	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.9600 to $117.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.0000 to $118.7100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.9600 to $117.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.0000 to $118.7100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.